Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcadia Biosciences (RKDA) Shares Outstanding (Weighted Average) (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Shares Outstanding (Weighted Average) for 12 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) changed 0.29% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Sep 2025, changed 0.29%, and an annual FY2024 reading of $1.4 million, up 10.22% over the prior year.
  • Shares Outstanding (Weighted Average) was $1.4 million for Q3 2025 at Arcadia Biosciences, roughly flat from $1.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $21.7 million in Q2 2021 and bottomed at $532016.0 in Q4 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $4.2 million, with a median of $1.4 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 133.14% in 2021, then tumbled 97.45% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $532016.0 in 2021, then rose by 12.66% to $599389.0 in 2022, then surged by 106.37% to $1.2 million in 2023, then grew by 10.22% to $1.4 million in 2024, then grew by 0.25% to $1.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for RKDA at $1.4 million in Q3 2025, $1.4 million in Q2 2025, and $1.4 million in Q1 2025.